I’ve narrowed the spotlight to three tools that consistently beat GPTZero, Turnitin, and Copyleaks in independent ...

CRISPR Therapeutics AG CRSP shares soared 8.7% in the last trading session to close at $76.78. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...

A red quarter of a circle with the words 'The Quarter Mark' beside it. A year-long series looking back on the most significant moments of the past 25 years, how they changed our world, and how they ...

St. Jude researchers advance CASTs, enhancing precision and activity for next-generation genome-editing therapies.

NEW YORK, NY – Two prominent biotechnology companies, Vertex Pharmaceuticals and CRISPR Therapeutics, both led by Indian American CEOs, have been named to TIME’s 2025 list of the 100 Most Influential ...

In the latest close session, CRISPR Therapeutics AG (CRSP) was down 6.54% at $68.29. The stock trailed the S&P 500, which registered a daily gain of 1.56%. On the other hand, the Dow registered a gain ...

Fintel reports that on October 10, 2025, Needham reiterated coverage of CRISPR Therapeutics (NasdaqGM:CRSP) with a Buy recommendation. Analyst Price Forecast Suggests 11.29% Upside As of September 30, ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A small S.F. biotech with ties ...

Is it the invasion of the genome snatchers? Just in case the idea of aliens walking around in human skin suits wasn’t frightening enough. An outlandish study asserts that aliens might have abducted us ...

Algen Biotechnologies’ unique functional genomics technologies tease apart complex disease biology using human-centric therapeutic endpoints to identify novel targets and best-in-class molecules.

As more patients with sickle cell disease or β-thalassemia are treated with the gene-edited cellular drug exa-cel, there are more opportunities to test for potential off-target editing. The authors ...